Transaction · 0001787306-25-000040

Welgus Howard G.

Welgus Howard G., DIR, reported an open-market or private sale at Arcutis Biotherapeutics, Inc. involving 10000.000000 shares for an estimated $130048.00. Reported holdings after the transaction were 131944.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SDIR
ARQTArcutis Biotherapeutics, Inc.
Filing timeMar 05
Trade dateMar 03, 2025
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
—
Pre-filing
1mo ago1w ago1d ago
Returns since
7d30d90d180d1y

ARQT price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
ARQT since 2025-03-05Filed 547 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001787306-25-000040
Common Stock
Transaction date
Mar 03, 2025
Filed Mar 05, 2025, 12:43 AM · 2d delay
Shares
10.0k sh
$1.30k per share
Estimated value
-$13.0M
Computed from shares × price
Holdings after
131k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Direct Ownership Repeat Seller 10b5-1 Detected
0score
Filing-only score

0

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

No officer title

Officer NoDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on March 5, 2024, by the Reporting Person, with a plan end date of May 30, 2025.

  2. F2

    The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $12.68 to $13.69, inclusive. The Reporting Person hereby undertake…

Original filing · 0001787306-25-000040
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

ARQT